FDA approves first gene therapy for rare metabolic disorder

The U.S. Food and Drug Administration has approved the first gene therapy for glycogen storage disease type Ia, a rare inherited condition that disrupts normal metabolism. Individuals with this disorder must regularly consume cornstarch to prevent dangerously low blood sugar levels. Clinical trials demonstrated that patients receiving the therapy required less frequent cornstarch intake compared to those on a placebo, marking a potential shift in treatment approaches. This approval extends to adults and children aged eight and older, providing a new option alongside traditional nutritional management. The therapy’s development addresses a long-standing challenge for those living with the condition, offering hope for improved quality of life and reduced reliance on dietary interventions. While the therapy is not a cure, its approval represents a milestone in genetic medicine for rare diseases with limited treatment options. Experts emphasize the need for further research to fully understand its long-term effects and benefits in broader patient populations. The decision underscores the FDA’s commitment to advancing therapies for conditions with significant unmet medical needs.